Background
Phase III, open-label RCT. 5018 women with HR+/HER2-negative N1 (1–3 positive nodes) early breast cancer and Oncotype DX recurrence score (RS) 0–25. Designed to address whether chemotherapy adds benefit to endocrine therapy in node-positive patients with low/intermediate genomic risk. Enrolled pre- and postmenopausal women — menopausal status emerged as a key effect modifier.
Interventions and follow up
Arm A: Chemotherapy + endocrine therapy (chemo regimen per investigator choice)
Arm B: Endocrine therapy alone (tamoxifen ± ovarian function suppression if premenopausal; AI if postmenopausal)
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 56.2 months
Arm B: Endocrine therapy alone (tamoxifen ± ovarian function suppression if premenopausal; AI if postmenopausal)
Primary endpoint: Invasive disease-free survival (IDFS)
mFollow up: 56.2 months
Results
IDFS (premenopausal, chemo vs ET): HR 0.60, 95% CI 0.43–0.83, P=.002 — chemo benefit
IDFS (postmenopausal, chemo vs ET): HR 0.97, 95% CI 0.78–1.22 — no chemo benefit
5-yr IDFS (postmenopausal, ET alone): 91.6% — excellent
IDFS (postmenopausal, chemo vs ET): HR 0.97, 95% CI 0.78–1.22 — no chemo benefit
5-yr IDFS (postmenopausal, ET alone): 91.6% — excellent
Adverse events
Chemotherapy-related: Standard chemo toxicities (alopecia, nausea, myelosuppression) in the chemo arm.
Reproductive: Chemotherapy-induced amenorrhea in premenopausal patients.
De-escalation benefit: Postmenopausal patients in the ET-alone arm were spared chemotherapy toxicity without compromising outcomes.
Reproductive: Chemotherapy-induced amenorrhea in premenopausal patients.
De-escalation benefit: Postmenopausal patients in the ET-alone arm were spared chemotherapy toxicity without compromising outcomes.
Conclusions
Postmenopausal women with HR+/HER2- N1 early BC and RS 0–25 derived no benefit from chemotherapy; ET alone is the standard of care. Premenopausal women with the same profile benefited from chemotherapy — benefit may partly reflect chemotherapy-induced ovarian suppression. RxPONDER extended Oncotype DX utility to node-positive disease.
Key Limitations
The chemotherapy benefit in premenopausal patients is confounded by chemotherapy-induced ovarian suppression — the benefit of ovarian suppression alone (without cytotoxicity) in premenopausal RS 0–25 N1 patients is not fully established. The RS threshold ≤25 captures most N1 patients, but RS ≥26 was not tested. Median follow-up is relatively short (56 months) — distant relapse events may increase for HR+ disease. Node count (1–3) was not fully stratified for subgroup analyses.
Clinical Context
RxPONDER transformed N1 chemotherapy decision-making. Postmenopausal women with RS 0–25 and 1–3 positive nodes can safely omit chemotherapy — a major de-escalation finding. Premenopausal women with N1 disease and RS 0–25 still require chemotherapy or discussion about whether chemotherapy-driven ovarian suppression is the mechanism of benefit. ASCO guidelines now integrate RxPONDER for N1 HR+ decision-making. ESMO-MCBS: not applicable.
References